The Landscape of Potential Targeted Treatments and Chemotherapy Efficacy Biomarkers for TNBC Authors: Yujuan Kang, Yanqing Liu, Zhi Liang, Song Zhang, Guangdong Qiao Published: 2025 ABSTRACT AbstractTriple negative breast cancer (TNBC) is characterized as an estrogen receptor (ER) negative, progesterone receptor (PR) negative, and human epidermal growth factor receptor (HER-2) negative disease with an enhanced systemic metastatic incidence, chemotherapeutic insensitivity, and drug resistance. The internal characteristics of TNBC are extraordinary complex and are accompanied by numerous gene mutations and constitutively activated signaling networks, which, in turn, augment TNBC malignancy. There is an urgency to uncover new and potent therapeutic targets for TNBC. Herein, we discussed the historical as well as newly discovered subtypes and properties of TNBC. We also presented a systematic outline of the aberrant gene expression and abnormal activated signaling networks in TNBC. Subsequently, we summarized the corresponding targeted therapeutic drugs, and reviewed the current targeted TNBC therapies launched in clinical trials, thereby providing a direction for future TNBC therapy. We also provided a detailed list of coding genes involved in chemo-sensitive and chemo-resistance of TNBC, which can potentially serve as indicators of chemotherapeutic efficacy. Finally, we discussed the novel and future potential treatments of TNBC. This review highlighted the new era of TNBC treatment in the coming years and provided the gene expression profile of TNBC patients who may benefit from chemotherapy. Introduction About 2.1 million women suffer from breast cancer (BC) in a given year, and BC is the largest contributor of cancer-linked deaths among women.1 BC is immunohistochemically (IHC) stratified into five sub-cohorts, namely, Luminal A, Luminal B, HER2, TNBC, and Normal-Like BC.2 TNBC, marked with no ER, PR, and HER2 contents, make up approximately 15–20% of all BC patients.3 TNBC including six TNBC categories,4,5 namely, two Basal-Like (BL1 and BL2), a mesenchymal (M), a mesenchymal stem-like (MSL), an immunomodulatory (IM), and a luminal androgen receptor (LAR).5 Due to the poor response of TNBC patients to anti-HER2 monoclonal antibodies (mAb)-based and endocrine interventions, classic anticancer treatments, such as, surgery, radiotherapy, and chemotherapy remain the primary strategies for treating TNBC.6 Among TNBC patients, disease progression and recurrence are common within the initial 3–5 years following diagnosis, and distant metastases frequently occur in the brain and lung.7 The primary TNBC intervention is chemotherapy. Anthracyclines and Taxanes are the most effective drugs.8 Even though 30% of TNBC patients respond adequately to chemotherapy and have good prognosis, presently, there are no available interventions for chemo-resistant patients.9 Among an unselected TNBC population, BRCA mutation incidence is about 20%.10 Emerging evidences revealed that platinum agent introduction in metastatic and neoadjuvant settings achieves satisfactory outcomes in patients with BRCA mutations.11,12 Furthermore, others have successfully employed poly ADP-ribose polymerase (PARP) inhibitors to cure TNBCs with BRCA mutations.13 With growing advancements in medicinal technology, immunotherapeutic agents have emerged as drugs with robust responses and enhancements in patient overall survival (OS).14 TNBC exhibits excess tumor infiltrating lymphocytes (TILs),15 relative to other subtypes, along with markedly enhanced PD-L1 expression16 and OS strongly linked to the severity of immune cell invasion.17 Hence, immune checkpoint blockade (ICB) therapies, such as, programmed death-1 (PD-1)- or programmed death-ligand 1 (PD-L1)-specific antibodies were shown to be highly efficacious in suppressing TNBC development.18,19 In addition, dysregulated gene expression and signaling networks are the most prominent feature of TNBC.20 Presently, several molecular targeted drugs are recognized as crucial for the treatment of TNBC. Notably, even though some TNBC patients are responsive to chemotherapy, there is still a considerable need for novel targeted therapeutic strategy discovery.21 In this review, we summarized the abnormal TNBC gene expression landscape, existing molecular targeted treatments, and chemotherapeutic efficacy biomarkers from the following four aspects: (1) The Molecular Subtypes of TNBC; (2) The Essential Characteristics and Potential Molecular Targeted Therapy of TNBC; (3) Coding Genes Involved in Chemo-Sensitive and Chemo-Resistance of TNBC; (4) Potential Novel Therapeutic Targets for TNBC. Results The Molecular Subtypes of TNBC TNBC is a diverse disease that displays considerable differences in pathological characteristics, physiological activities, and genetic profiles.5,22 The established TNBC subtypes are BL1, BL2, M, MSL, IM, and LAR,5 and they are all unique in their features. The BL1 subtype is characterized by enhanced MYC, PI3K catalytic subunit α (PIK3CA), CDK6, AKT2, KRAS, FGFR1, IGF1R, CCNE1, and CDKN2A/B amplification, and augmented prevalence of heterozygous or homozygous deletion of DNA repair-associated genes (BRCA2, PTEN [phosphatase and tensin homolog], MDM2, RB1, and TP53). It is often combated with PARP inhibitors (PARPi) and genotoxic agents.23 The BL2 subtype features aberrant activation of EGFR, MET, NGF, Wnt/β-catenin, and IGF-1R pathway activations, and it is treated with mTOR inhibitors and growth factor inhibitors.23 The M subtype features constitutive stimulation of the cell migration-associated axis, extracellular matrix-receptor association network, and differentiation axes [Wnt, anaplastic lymphoma kinase, transforming growth factor (TGF)-β],23 and it is targeted with mTOR inhibitors and drugs against the epithelial-mesenchymal-transition (EMT).24 The MSL subtype exhibited markedly reduced cell proliferation-associated genes, with simultaneous elevations in the stemness-associated genes (ABCA8, PROCR, ENG, ALDHA1, PER1, ABCB1, TERT2IP, BCL2, BMP2, and THY), HOX genes (HOXA5, HOXA10, MEIS1, MEIS2, MEOX1, MEOX2, and MSX1), and mesenchymal stem cell (MSC) markers (BMP2, ENG, ITGAV, KDR, NGFR, NT5E, PDGFR, THY1, and VCAM1), and this is managed using PI3K inhibitors, v-src sarcoma viral oncogene homolog (Src) antagonists, or antiangiogenic drugs. A Src inhibitor (Dasatinib) may also be used to treat M and MSL TNBC.23 Of note, the M and MSL categories are linked to an enhanced angiogenesis signature score.25 The IM subtype is featured with abundant immune signaling networks, including, Th1/Th2, NK cell, B cell receptor, dendritic cell (DC), T cell receptor, interleukin (IL)-12, and IL-7 networks, and this category is treated with immune checkpoint inhibitor (ICI).23 The LAR subtype have enhanced AR signaling, as is evidenced by IHC, which depicts upregulated AR, downstream genes, and auxiliary activators (DHCR24, ALCAM, FASN, FKBP5, APOD, PIP, SPDEF, and CLDN8).26,27 LAR tumors also contain PI3KCA (55%), AKT1 (13%) and CDH1 (13%) gene mutations.25 LAR responds to anti-AR therapy.5 With advancements in medical technology, there have emerged certain modification to TNBC stratification. Burstein et al proposed a four subtypes classification of TNBC, including, LAR, mesenchymal (MES), basal-like immunosuppressed (BLIS), and basal-like immune activated (BLIA).28 The potential corresponding targets were also identified as follows: (i) LAR: AR and MUC1, (ii) MES: growth factor receptors, (iii) BLIS: an immunosuppressing molecule (VTCN1), and (iv) BLIA: STAT-related molecules and cytokines.28 Alternatively, Zhao et al identified AR, CD8, FOXC1, and DCLK1 as TNBC bioindicators, and stratified TNBCs into five categories, based on IHC: (a) IHC-based LAR (IHC-LAR; AR-positive [+]), (b) IHC-based immunomodulatory (IHC-IM; AR-negative [−], CD8+), (c) IHC-based basal-like immune-suppressed (IHC-BLIS; AR−, CD8−, FOXC1+), (d) IHC-based mesenchymal (IHC-MES; AR−, CD8−, FOXC1−, DCLK1+), and (e) IHC-based unclassifiable (AR−, CD8−, FOXC1−, DCLK1−). The IHC-LAR category is marked with a strongly activated HER2 network. The IHC-IM category has CD8+ T cell invasion into the tumor parenchyma. The IHC-BLIS category has an enhanced VEGF expression. The IHC-MES category is featured by active JAK/STAT3 axis.29 He et al stratified TNBC according to immune profiles as follows: High (Immunity_H), Medium (Immunity_M), and Low (Immunity_L). Immunity_H displays a vast immune cell invasion and anti-tumor immunologic activity. Among its immune signatures are excess cellular apoptosis, as well as calcium, MAPK, PI3K–Akt, and RAS networks. Alternatively, Immunity_L presents with a diminished immune profile and enhanced cellular cycle, Hippo axis, DNA replication, mismatch repair, cell adhesion molecule interaction, spliceosome, adherens junction activity, pyrimidine metabolism, glycosylphosphatidylinositol-anchor biosynthesis, and RNA polymerase networks. There are five transcription factor (TF) genes that are specific to the Immunity_H category, namely, CORO1A, STAT4, BCL11B, ZNF831, and EOMES, and two that are specific to the Immunity_L category, namely, IRF8 and SPI1.30 These TNBC classifications facilitate an elevated level of understanding of TNBC (Table 1). Table 1The Subgroups and Properties of TNBCTNBCER (-)PR (-)HER2 (-)PropertiesTherapyRefLehmann et alBasal-Like 1 (BL1)(a) High expression of MYC, PIK3CA, CDK6, AKT2, KRAS, FGFR1, IGF1R, CCNE1, CDKN2A/B; (b)Augmented prevalence of heterozygous or homozygous deletion of DNA repair-associated genes (BRCA2, PTEN, MDM2, RB1, and TP53)PARPi; Genotoxic Agents[5, 23]Basal-Like 2 (BL2)(a) Activation of EGFR, MET, NGF, Wnt/β-catenin, IGF-1R pathwaysmTOR Inhibitors; Growth Factor Inhibitors[5, 23]Mesenchymal (M)Activated cell migration- associated axis, extracellular matrix–receptor network, and differentiation axes (Wnt, anaplastic lymphoma kinase, TGF-β); (b) Higher signature score for angiogenesismTOR Inhibitors; Drugs against EMT; Src Inhibitor[5, 23–25]Mesenchymal stem-like (MSL)Reduced cell proliferation-related genes;Elevation in the stemness-related genes (ABCA8, PROCR, ENG, ALDHA1, PER1, ABCB1, TERT2IP, BCL2, BMP2, and THY);Elevation in the HOX genes (HOXA5, HOXA10, MEIS1, MEIS2, MEOX1, MEOX2, and MSX1);Elevation in the MSC-specific markers (BMP2, ENG, ITGAV, KDR, NGFR, NT5E, PDGFR, THY1, and VCAM1);Higher signature score for angiogenesis;PI3K Inhibitors; Src Inhibitor; Antiangiogenic drugs[5, 23, 25]Immunomodulatory (IM)Enriched immune related signaling networks, including, Th1/Th2, NK cell, B cell receptor, dendritic cell (DC), T cell receptor, interleukin (IL)-12, and IL-7 networksICI[5, 23]Luminal Androgen Receptor (LAR)Enhanced AR signaling, downstream genes, and auxiliary activators (DHCR24, ALCAM, FASN, FKBP5, APOD, PIP, SPDEF, and CLDN8)(b) Contain PI3KCA (55%), AKT1 (13%) and CDH1 (13%) gene mutationsAR Antagonist (Bicalutamide)[5, 25–27]Burstein et alLuminal androgen receptor (LAR)AR and MUC1[28]Mesenchymal (MES)Growth factor receptorsBasal-like immunosuppressed (BLIS)Immunosuppressing molecule (VTCN1)Basal-like immune activated (BLIA)STAT-related molecules and cytokinesZhao et alIHC-based LAR (IHC-LAR; AR-positive [+])Activation of HER2 network[29]IHC-based immunomodulatory (IHC-IM; AR-negative [−], CD8+)CD8+ T cell invasion into the tumor parenchymaIHC-based basal-like immune-suppressed (IHC-BLIS; AR−, CD8−, FOXC1+)Enhanced VEGF expressionIHC-based mesenchymal (IHC-MES; AR−, CD8−, FOXC1−, DCLK1+)Active JAK/STAT3 axisIHC-based unclassifiable (AR−, CD8−,FOXC1−, DCLK1−)UnknownHe et alImmunity High (Immunity_H)(a) Excess cellular apoptosis, as well as calcium, MAPK, PI3K–Akt, and RAS networks; (b) Express five TF genes (CORO1A, STAT4, BCL11B, ZNF831, and EOMES)[30]Immunity Medium (Immunity_M)In the middleImmunity Low (Immunity_L)(a) Diminished immune profile and enhanced cellular cycle, Hippo axis, DNA replication, mismatch repair, cell adhesion molecule interaction, spliceosome, adherens junction activity, pyrimidine metabolism, glycosylphosphatidylinositol-anchor biosynthesis, and RNA polymerase networks Table 1The Subgroups and Properties of TNBCTNBCER (-)PR (-)HER2 (-)PropertiesTherapyRefLehmann et alBasal-Like 1 (BL1)(a) High expression of MYC, PIK3CA, CDK6, AKT2, KRAS, FGFR1, IGF1R, CCNE1, CDKN2A/B; (b)Augmented prevalence of heterozygous or homozygous deletion of DNA repair-associated genes (BRCA2, PTEN, MDM2, RB1, and TP53)PARPi; Genotoxic Agents[5, 23]Basal-Like 2 (BL2)(a) Activation of EGFR, MET, NGF, Wnt/β-catenin, IGF-1R pathwaysmTOR Inhibitors; Growth Factor Inhibitors[5, 23]Mesenchymal (M)Activated cell migration- associated axis, extracellular matrix–receptor network, and differentiation axes (Wnt, anaplastic lymphoma kinase, TGF-β); (b) Higher signature score for angiogenesismTOR Inhibitors; Drugs against EMT; Src Inhibitor[5, 23–25]Mesenchymal stem-like (MSL)Reduced cell proliferation-related genes;Elevation in the stemness-related genes (ABCA8, PROCR, ENG, ALDHA1, PER1, ABCB1, TERT2IP, BCL2, BMP2, and THY);Elevation in the HOX genes (HOXA5, HOXA10, MEIS1, MEIS2, MEOX1, MEOX2, and MSX1);Elevation in the MSC-specific markers (BMP2, ENG, ITGAV, KDR, NGFR, NT5E, PDGFR, THY1, and VCAM1);Higher signature score for angiogenesis;PI3K Inhibitors; Src Inhibitor; Antiangiogenic drugs[5, 23, 25]Immunomodulatory (IM)Enriched immune related signaling networks, including, Th1/Th2, NK cell, B cell receptor, dendritic cell (DC), T cell receptor, interleukin (IL)-12, and IL-7 networksICI[5, 23]Luminal Androgen Receptor (LAR)Enhanced AR signaling, downstream genes, and auxiliary activators (DHCR24, ALCAM, FASN, FKBP5, APOD, PIP, SPDEF, and CLDN8)(b) Contain PI3KCA (55%), AKT1 (13%) and CDH1 (13%) gene mutationsAR Antagonist (Bicalutamide)[5, 25–27]Burstein et alLuminal androgen receptor (LAR)AR and MUC1[28]Mesenchymal (MES)Growth factor receptorsBasal-like immunosuppressed (BLIS)Immunosuppressing molecule (VTCN1)Basal-like immune activated (BLIA)STAT-related molecules and cytokinesZhao et alIHC-based LAR (IHC-LAR; AR-positive [+])Activation of HER2 network[29]IHC-based immunomodulatory (IHC-IM; AR-negative [−], CD8+)CD8+ T cell invasion into the tumor parenchymaIHC-based basal-like immune-suppressed (IHC-BLIS; AR−, CD8−, FOXC1+)Enhanced VEGF expressionIHC-based mesenchymal (IHC-MES; AR−, CD8−, FOXC1−, DCLK1+)Active JAK/STAT3 axisIHC-based unclassifiable (AR−, CD8−,FOXC1−, DCLK1−)UnknownHe et alImmunity High (Immunity_H)(a) Excess cellular apoptosis, as well as calcium, MAPK, PI3K–Akt, and RAS networks; (b) Express five TF genes (CORO1A, STAT4, BCL11B, ZNF831, and EOMES)[30]Immunity Medium (Immunity_M)In the middleImmunity Low (Immunity_L)(a) Diminished immune profile and enhanced cellular cycle, Hippo axis, DNA replication, mismatch repair, cell adhesion molecule interaction, spliceosome, adherens junction activity, pyrimidine metabolism, glycosylphosphatidylinositol-anchor biosynthesis, and RNA polymerase networks The Subgroups and Properties of TNBC Activated cell migration- associated axis, extracellular matrix–receptor network, and differentiation axes (Wnt, anaplastic lymphoma kinase, TGF-β); (b) Higher signature score for angiogenesis Activated cell migration- associated axis, extracellular matrix–receptor network, and differentiation axes (Wnt, anaplastic lymphoma kinase, TGF-β); (b) Higher signature score for angiogenesis Reduced cell proliferation-related genes; Reduced cell proliferation-related genes; Elevation in the stemness-related genes (ABCA8, PROCR, ENG, ALDHA1, PER1, ABCB1, TERT2IP, BCL2, BMP2, and THY); Elevation in the stemness-related genes (ABCA8, PROCR, ENG, ALDHA1, PER1, ABCB1, TERT2IP, BCL2, BMP2, and THY); Elevation in the HOX genes (HOXA5, HOXA10, MEIS1, MEIS2, MEOX1, MEOX2, and MSX1); Elevation in the HOX genes (HOXA5, HOXA10, MEIS1, MEIS2, MEOX1, MEOX2, and MSX1); Elevation in the MSC-specific markers (BMP2, ENG, ITGAV, KDR, NGFR, NT5E, PDGFR, THY1, and VCAM1); Elevation in the MSC-specific markers (BMP2, ENG, ITGAV, KDR, NGFR, NT5E, PDGFR, THY1, and VCAM1); Higher signature score for angiogenesis; Higher signature score for angiogenesis; Enriched immune related signaling networks, including, Th1/Th2, NK cell, B cell receptor, dendritic cell (DC), T cell receptor, interleukin (IL)-12, and IL-7 networks Enriched immune related signaling networks, including, Th1/Th2, NK cell, B cell receptor, dendritic cell (DC), T cell receptor, interleukin (IL)-12, and IL-7 networks Enhanced AR signaling, downstream genes, and auxiliary activators (DHCR24, ALCAM, FASN, FKBP5, APOD, PIP, SPDEF, and CLDN8) Enhanced AR signaling, downstream genes, and auxiliary activators (DHCR24, ALCAM, FASN, FKBP5, APOD, PIP, SPDEF, and CLDN8) The Essential Characteristics and Potential Molecular Targeted Therapy of TNBC TNBC prognosis is generally worse than non-TNBC.8,31,32 Although chemotherapy is the primary intervention for TNBC, it often produces rather disappointing outcomes. Due to the lack of precision therapeutic targets, TNBC is often aggressive in BC patients.33,34 TNBC is a heterogeneous tumor, accompanied by dysregulated gene expression and constitutively activated signaling networks. In this report, we provide a detailed list of gene mutations and aberrantly activated signaling networks in TNBC, as well as corresponding treatment methods for TNBC, based on the following aspects: (a) DNA Damage Response (DDR)-Related BRCA Loss-Function Mutation; (b) PI3K Signaling Network; (c) NOTCH Signaling Network; (d) CDK-Rb Signaling Network; (e) EGFR Activation; (f) Angiogenesis Signaling Network; (g) HER2-Low TNBC; (h) DDR Signaling Network (i) Immunotherapy, and (j) Androgen Receptor (AR) (Figure 1 and Table 2). Table 2The Molecular Targeted Medicines of TNBCDrug TypeDrugs NameTargeted Gene/Signaling PathwayRefPARP InhibitorsOlaparib; Rucaparib; Niraparib; Talazoparib; VeliparibBRCA1/2[35]PI3K InhibitorsBuparlisib; SAR245408; Taselisib; PX-866; Alpelisib; SerabelisibPI3K[36–41]AKT InhibitorsIpatasertib; Perifosine; MK2206; AZD5363AKT[42–46]mTOR InhibitorsTemsirolimus; EverolimusmTOR[47]Dual PI3K/AKT/mTOR InhibitorsApitolisib; Omipalisib; AZD2014; Voxtalisib; Dactolisib; GDC-0980PI3K/AKT/mTOR[48–53]Notch InhibitorsAL101Notch[54, 55]CDK4/6 InhibitorsFlavopiridol; Palbociclib; Ribociclib, Abemaciclib; LEE011; LY2835219CDK-Rb Pathway[56–58]EGFR TKIErlotinib; GefitinibEGFR[59]Anti-EGFR mAbAfatinib; LapatinibEGFR and ERBB2[59]VEGFR mAbBevacizumab; Sunitinib; RamucirumabVEGF-A and VEGFR[60–62]Anti-angiogenicSemaphorinsNRP1 and NRP2[63]VEGF decoy receptorAfliberceptVEGFR[64]FGFR InhibitorsAZD4547; BGJ398; BLU9931; Debio-1347; Dovitinib; FIIN-2; JNJ-42756493; LY2874455; PonatinibFGFR[65–74]Anti-HER2 ADCTrastuzumab Deruxtecan; Trastuzumab Duocarmazine; Disitamab Vedotin; MRG002HER2[75]Anti-HER2 TKIsNeratinib; Poziotinib; PyrotinibHER2[76]ATR InhibitorsVX-970; AZD6738ATR-CHK1-WEE1[35]CHK1 InhibitorsAZD7762; V158411; LY2606368; UCN-01ATR-CHK1-WEE1[77–80]WEE InhibitorsAZD1775ATR-CHK1-WEE1[81]CTLA-4 InhibitorsIpilimumab; TremelimumabCTLA-4[82]PD-1 InhibitorsPembrolizumab; Pidilizumab; NivolumabPD-1[83]PD-L1 InhibitorsAtezolizumabPD-L1[83]AR InhibitorsBicalutamide; Enzalutamide; SeviteronelAR[84]Ferroptosis related drugs1-methyl-3-isobutylxanthine; RosiglitazoneFerroptosis Pathway[85]Targeted ADC bioindicatorsSacituzumab Govitecan (IMMU-132); Ladiratuzumab vedotin (SGN-LIV1A); Glembatumumab Vedotin (CDX-011); AVID100; U3-1402; CAB-ROR2-ADC; SAR566658Trop-2; LIV1; EGFR; gpNMB; EGFR; HER3; ROR2; DS6[86–89]CeritinibCeritinibRTK-ACK1/FAK-AR[90, 91]Src InhibitorDasatinibSrc[92–96]CDK12/CDK13 InhibitorSR-4835CDK12/CDK13[97] Figure 1The abnormal gene and cell signal transduction profiles, as well as corresponding targeted TNBC therapy. (a) DNA Damage Response (DDR)-Related BRCA Loss-Function Mutation; (b) PI3K Signaling Network; (c) NOTCH Signaling Network; (d) CDK-Rb Signaling Network; (e) EGFR Activation; (f) Angiogenesis Signaling Network; (g) HER2-Low TNBC; (h) DDR Signaling Network (i) Immunotherapy, and (j) Androgen Receptor (AR). Table 2The Molecular Targeted Medicines of TNBCDrug TypeDrugs NameTargeted Gene/Signaling PathwayRefPARP InhibitorsOlaparib; Rucaparib; Niraparib; Talazoparib; VeliparibBRCA1/2[35]PI3K InhibitorsBuparlisib; SAR245408; Taselisib; PX-866; Alpelisib; SerabelisibPI3K[36–41]AKT InhibitorsIpatasertib; Perifosine; MK2206; AZD5363AKT[42–46]mTOR InhibitorsTemsirolimus; EverolimusmTOR[47]Dual PI3K/AKT/mTOR InhibitorsApitolisib; Omipalisib; AZD2014; Voxtalisib; Dactolisib; GDC-0980PI3K/AKT/mTOR[48–53]Notch InhibitorsAL101Notch[54, 55]CDK4/6 InhibitorsFlavopiridol; Palbociclib; Ribociclib, Abemaciclib; LEE011; LY2835219CDK-Rb Pathway[56–58]EGFR TKIErlotinib; GefitinibEGFR[59]Anti-EGFR mAbAfatinib; LapatinibEGFR and ERBB2[59]VEGFR mAbBevacizumab; Sunitinib; RamucirumabVEGF-A and VEGFR[60–62]Anti-angiogenicSemaphorinsNRP1 and NRP2[63]VEGF decoy receptorAfliberceptVEGFR[64]FGFR InhibitorsAZD4547; BGJ398; BLU9931; Debio-1347; Dovitinib; FIIN-2; JNJ-42756493; LY2874455; PonatinibFGFR[65–74]Anti-HER2 ADCTrastuzumab Deruxtecan; Trastuzumab Duocarmazine; Disitamab Vedotin; MRG002HER2[75]Anti-HER2 TKIsNeratinib; Poziotinib; PyrotinibHER2[76]ATR InhibitorsVX-970; AZD6738ATR-CHK1-WEE1[35]CHK1 InhibitorsAZD7762; V158411; LY2606368; UCN-01ATR-CHK1-WEE1[77–80]WEE InhibitorsAZD1775ATR-CHK1-WEE1[81]CTLA-4 InhibitorsIpilimumab; TremelimumabCTLA-4[82]PD-1 InhibitorsPembrolizumab; Pidilizumab; NivolumabPD-1[83]PD-L1 InhibitorsAtezolizumabPD-L1[83]AR InhibitorsBicalutamide; Enzalutamide; SeviteronelAR[84]Ferroptosis related drugs1-methyl-3-isobutylxanthine; RosiglitazoneFerroptosis Pathway[85]Targeted ADC bioindicatorsSacituzumab Govitecan (IMMU-132); Ladiratuzumab vedotin (SGN-LIV1A); Glembatumumab Vedotin (CDX-011); AVID100; U3-1402; CAB-ROR2-ADC; SAR566658Trop-2; LIV1; EGFR; gpNMB; EGFR; HER3; ROR2; DS6[86–89]CeritinibCeritinibRTK-ACK1/FAK-AR[90, 91]Src InhibitorDasatinibSrc[92–96]CDK12/CDK13 InhibitorSR-4835CDK12/CDK13[97] The Molecular Targeted Medicines of TNBC The abnormal gene and cell signal transduction profiles, as well as corresponding targeted TNBC therapy. (a) DNA Damage Response (DDR)-Related BRCA Loss-Function Mutation; (b) PI3K Signaling Network; (c) NOTCH Signaling Network; (d) CDK-Rb Signaling Network; (e) EGFR Activation; (f) Angiogenesis Signaling Network; (g) HER2-Low TNBC; (h) DDR Signaling Network (i) Immunotherapy, and (j) Androgen Receptor (AR). DDR-Related BRCA Loss-Function Mutation Among the cancer features are DNA damage and impaired repair.98 Prior reports demonstrated loss-of-function mutations in two essential BC susceptibility genes (BRCA1 and BRCA2) that modulate DDR, in 5% of BC patients.99–101 BRCA1 and BRCA2 proteins modulate DNA replication for stabilization and homologous recombination (HR).102 Based on one report, 70% of the inherited BRCA1 mutation-harboring BC patients and 16~23% of BRCA2 mutation-harboring BC patients are TNBC.103 TNBC PARP enzymes are essential to the base excision repair mechanism, and PARP1 and PARP2 modulate DDR process.104 BRCA1/2-mutated tumors tend to possess extra sensitivity toward PARP1 inhibition induced synthetic lethality. Thus, PARP1 inhibitors are promising for BRCA1/2 mutated patients.105 The PARPi Olaparib is highly potent as a monotherapy in BC patients.106 Presently, there are five BC-combating PARPi are under clinical validation: Olaparib, Rucaparib, Niraparib, Talazoparib, and Veliparib.35 Additionally, emerging preclinical and clinical investigations demonstrated strong efficacy of platinum-based chemotherapy among TNBC patients.107 Moreover, relevant clinical investigations were launched to accurately access the therapeutic effect of PARPi in TNBC and BC (https://clinicaltrials.gov/) (Supplemental Table 1). PI3K Signaling Network Dysregulated phosphoinositide 3-kinase (PI3K)/AKT/mTOR is a hallmark of cancerous development.105 This axis is essential for the receptor tyrosine kinase (RTK) signaling and tumor growth in BC.108 In fact, PI3K pathway mutations form a special subgroup among TNBC patients.20 In TNBC, the aberrant PI3K/AKT/mTOR axis activation is regulated by upstream regulator, activating PIK3CA mutations, PTEN loss of function or expression mutation, and proline-rich inositol poly-phosphatase (negative PI3K modulator) downregulation.109,110 Herein, we summarized the underlying mechanisms and PI3K signaling-targeted drugs associated with TNBC. PI3K Inhibitors In a previous report, it was revealed that pan-PI3K inhibitor (Buparlisib), combined with Buparlisib and Olaparib, diminishes BRCA1/2 content and encourages HR deficiency in BRCA1 WT TNBC patients.36 In addition, the pan-PI3K inhibitors (SAR245408, Taselisib, and PX-866) are undergoing studied for HER2+ and HR+ BC.37–39 Alpelisib is an isoform-specific PI3K inhibitor under examination in clinical trials.40 Moreover, there is ongoing development of Serabelisib, a robust and targeted PIK3CA inhibitor for management of solid tumors.41 The relevant clinical trials are listed in Supplemental Table 1. AKT Inhibitors Ipatasertib inhibits AKT which is downstream of PI3K.42 Early AKT inhibitors, namely, Perifosine and MK2206, exhibited no clinical significance in Phase II trials,43 however, novel AKT inhibitors appear to be highly promising in Phase I trials.44,45 Other AKT inhibitors (AZD5363) are under clinical development either as a mono- or chemo-combined therapy or as targeted agents for TNBC therapy.43,46 Supplemental Table 1 summarizes the related clinical trials. mTOR Inhibitors A phase I investigation explored the synergistic effect of the chemotherapeutic doxorubicin, antiangiogenic bevacizumab, and mTOR inhibitors (Temsirolimus, Everolimus) in TNBC patients.47 Clinical trials related with them are provided Supplemental Table 1. Dual PI3K/AKT/mTOR Inhibitors Apitolisib is a PI3K inhibitor that also targets mTORC.48 Omipalisib is reported to have strong pan-PI3K and mTORC suppression abilities in a HER2+ model.49 Preclinical information confirmed the mTORC1/2 inhibitor AZD2014-based inhibition of p-AKT, relative to everolimus in TNBC patient-based xerograph models.50 Voxtalisib is another PI3K and mTOR inhibitor that is presently under investigation in clinical trials as a potential HR+ tumor treatment.51 Dual PI3K/AKT/mTOR inhibitors are often administered alongside other drugs. Dactolisib is a potential PI3K and mTOR inhibitor that will supplement MEK162 (a MEK inhibitor) therapy in treated TNBC.52 De et al also reported that the synergistic effect of GDC-0980 (pan-PI3K and mTOR inhibitor) and ABT888 (a PARPi) significantly suppressed tumor development in a PTEN-null TNBC model.53 Clinical trials are summarized in Supplemental Table 1. NOTCH Signaling Network The NOTCH axis is a robust bioindicator of TNBC. Notch gain of function mutations occured in 10% of TNBC patients. The NOTCH signaling pathway utilizes four distinct receptor types (Notch-1 through Notch-4) which interact with five specific ligand molecules (Delta-like 1, 3, and 4 along with Jagged proteins 1 and 2).54 AL101 is currently being developed as a pan-Notch inhibitor of the NOTCH network.55 Relevant clinical trials are summarized in Supplemental Table 1. CDK-Rb Signaling Network The cyclin-dependent kinases 4 and 6 (CDK4/6)–RB1 axis modulates the G1 phase restriction point of the cell cycle, and cancers often impair this signal transduction to initiate constitutively active cell proliferation.111,112 Mutations and aberrations impacting the Rb axis are another hallmark of TNBC etiology.4,113 Pharmaceutics-based CDK4/6 inhibition (CDK4/6i) generally abrogates RB phosphorylation, thereby affecting the G1/S checkpoint.114 More recently, it was revealed that RB-harboring TNBC are highly responsive to CDK4/6 inhibition, thereby providing ample evidence of the strong potential of CDK4/6i as a successful TNBC therapy.21,115–117 Flavopiridol became the first broad-spectrum CDK inhibitor examined in clinical trials.56 Palbociclib, a specific CDK4/6 inhibitor, has been approved by the FDA for the treatment of ER-positive advanced BC57,58 and is expected to provide new treatment strategies for TNBC patients, especially the LAR subtype of TNBC.21 At present, there are three FDA-approved CDK4/6i: Palbociclib, Ribociclib, and Abemaciclib for BC patients. Two other CDK4/6i (LEE011 and LY2835219) are under examination in dose-screening Phase I investigations. Relevant clinical trials are presented in Supplemental Table 1. EGFR Activation Unlike non-TNBC,118,119 TNBCs exhibited close to 78% EGFR overexpression,118,120–123 indicating the possibility of using EGFR as a target for TNBC therapy. Among the reasons for EGFR overexpression in TNBC is EGFR gene amplification, which is highly variable and present in close to 24% TNBC patients,124–126 and EGFR gene mutation.124,126 Given these evidences, EGFR tyrosine kinase inhibitors (TKI) and anti-EGFR mAb have been examined alone and alongside chemotherapy in the early127,128 and metastatic stage of disease.129,130 TKIs like Erlotinib and Gefitinib target EGFR; anti-EGFR mAb, which include Afatinib and Lapatinib target EGFR and ERBB259 in TNBC therapy. The available clinical information involving Erlotinib, Afatinib, and Lapatinib usage are presented in Supplemental Table 1. Angiogenesis Signaling Network Angiogenesis critically modulates tumor growth.131 Vascular endothelial growth factor (VEGF) is the primary angiogenic modulator, and it is synthesized during BC.131 Angiogenic homeostasis is maintained via an intricate balance of pro- angiogenic agents (VEGF, FGF and PDGF, HIFs) and anti-angiogenic agents (thrombospondin, angiostatin and endostatin).132 VEGF are expressed in 30–60% of TNBC,133 thereby raising the possibility of an anti-VEGF based therapy for TNBC. Herein, we summarized relevant and potential therapies targeting angiogenesis in TNBC. VEGFR TNBC patients exhibit markedly elevated intra-tumoral VEGF rates, relative to non-TNBC patients.134 VEGF family includes five ligands (VEGFA, VEGFB, VEGFC, VEGFD, and placental growth factor), five receptors (VEGFR1, VEGFR2, VEGFR3, NRP1 and NRP2).132 Since angiogenesis is critical for tumor cell proliferation, Bevacizumab, a VEGF-A-binding mAb, has gained much attention as a potential TNBC therapeutic target.60 Under a neoadjuvant situation, bevacizumab is reported to strongly enhance pathological complete response (pCR).135 In addition, the VEGF axis-targeting interaction efficacy can potentially be modified using other ligands, such as, Semaphorins, that associate with both NRP1 and NRP2, suggesting that Semaphorins a potential may be new anti-angiogenic therapeutic target.63 Small molecule TKIs have been developed to prohibit angiogenesis through binding receptors.136 Sunitinib represents one such agent, binding multiple moieties including VEGFR1, VEGFR2, PDGFR and KIT.61 IMC-1121 (Ramucirumab) is a fully humanized mAb of VEGFR, and it is reported to demonstrate strong efficacy against BC.62 VEGF-Trap (Aflibercept) is a decoy VEGFR that potentially sequesters VEGF to disrupt its association with its true receptor.64 Ongoing clinical investigations evaluating the effectiveness of the aforementioned drugs are summarized in Supplemental Table 1. Fibroblast Growth Factor Receptors (FGFR) FGFRs belong to the trans-membranal receptor family that are crucial for angiogenic regulation.55 Tumor-based fibroblasts are ubiquitous present in BC, whereby they generate a myriad of growth factors, namely, basic fibroblast growth factor (bFGF).137 The bFGF-FGFR axis activation is a hallmark of carcinogenesis.138 FGFR1, FGFR2, FGFR3, and FGFR4 make up the FGFR family of RTKs.139–141 FGFR1 over-expression is typically found in 18% of TNBC patients, with the FGFR1 gene amplification accounting for 33% of cases,142 and FGFR2 amplification in <5% of cases.143 Clinical trials have reported favorable outcomes for both multi-targeted TKIs144 and FGFR-specific TKIs.145 Unlike TKIs, anti-FGFR isoform antibodies146 and FGF ligand inhibitors were also shown to have strong anti-TNBC efficacies.147 AZD4547,65,66 BGJ398 (Infigratinib),67 BLU9931,68 Debio-1347,69 Dovitinib (TKI258),70 FIIN-2,71 JNJ-42756493,72 LY287445573 and Ponatinib74 are small but robust molecular compounds that suppress FGFRs at reduced concentrations. Relevant clinical trials were hoped to develop in the future. HER2-Low TNBC A new stratification was proposed for BC with reduced HER2 content and undetectable gene amplification (IHC) 1+ or IHC 2+ with negative in situ hybridization (ISH). This is termed as HER2-low.55 Anti-HER2 agent technology has also been transformed from the classical binary stratification to the “HER2-low” BC classification.75 Antibody-drug conjugates (ADCs) are a relatively new anticancer therapy that facilitates the specific deployment of a robust cytotoxic “payload” to cancer cells via targeted association between antibody and cancer cell surface molecule.148 At present, multiple ADCs are being examined for drug efficacy and safety.149 Till now, four anti-HER2 ADCs were reported to produce strong anti-cancer activity among HER2-low BC patients: Trastuzumab Deruxtecan (DXd), Trastuzumab Duocarmazine, Disitamab Vedotin, and MRG002.75 The anti-HER2 ADC Dxd (DS-8201a) demonstrated satisfactory outcome in a Phase 1 investigation involving advanced HER2-low solid tumors, which including BC (NCT02564900). Trastuzumab Duocarmazine (SYD985) comprises an anti-HER2 antibody attached to a DNA-alkylating duocarmycin payload via a cleavable linker.75 Disitamab Vedotin (RC48-ADC) is an ADC made up of a new anti-HER2 humanized antibody, hertuzumab, which is attached to a microtubular inhibitor monomethyl auristatin E (MMAE) payload via a cleavable linker.75 MRG002 is a newly designed HER2-targeted ADC made up of modified trastuzumab linked with a cleavable linker to a MMAE payload.75 Several anti-HER2 vaccines are currently being examined among HER2-low BC population, among them, some displayed good outcome among TNBC patients.149,150 Anti-HER2 TKIs, Neratinib,76 and other anti-HER2 TKIs, namely, Poziotinib and Pyrotinib, are also under investigation as potential anti-cancer agents. Relevant clinical trials are provided in Supplemental Table 1. DDR Signaling Network TNBC patients exhibited a high frequency of distinctive DDR alterations.4,151–153 The DDR axis, which modulates damaged DNA repair and genomic stability maintenance, is, in turn, regulated by DNA damage sensors, cell cycle checkpoints, diverse DNA repair signals and cellular apoptosis.154,155 The ATR-CHK1-WEE1 axis is most targeted among all the DDR networks. VX-970 (VE-822 or Berzosertib) is a robust and specific ATR inhibitor, and the first ATR inhibitor to be examined in clinical trials. In another clinical trial, AZD6738 (Ceralasertib), a targeted ATR inhibitor, was employed as a second ATR inhibitor.35 The CHK1 inhibitor AZD7762 is an ATP-competitive dual CHK1/2 inhibitor, which exerts its primary antitumor property via CHK1 suppression.77 TNBC sensitivity to AZD7762 is substantially augmented by RB deficiency in vitro and in xenografts likely due to the non-existent RB enhanced DNA replication stress.78 V158411, another ATP-competitive CHK1/2 inhibitor, demonstrated marked cytotoxicity in TNBC versus HR+ BC. LY2606368 (Prexasertib) is a second-generation CHK1/2 dual inhibitor that selectively targets CHK1. LY2606368 monotherapy was proven to be safe and efficacious among high-grade ovarian carcinoma patients, who have numerous commonalities with TNBC patients.79 UCN-01 was the first proposed CHK1 inhibitor, and its synergistic effect with gemcitabine inhibits TNBC as UCN-01 drives the gemcitabine-induced S-phase cell arrest the through G2/M checkpoints, thereby augmenting DNA damage, and accelerating cellular death.80 Despite the recent emergence of several small-molecule WEE1 inhibitors, AZD1775 (Adavosertib) is the most studied, and only molecule to enter clinical trials till date.81 Relevant clinical trials are provided in Supplemental Table 1. Immunotherapy TNBC have strongly upregulated PD-1/PD-L1 levels. Consequently, scientists examined the efficacies of these checkpoint inhibitors in mono- and combined therapies, with modest outcome.156 CTLA-4, PD-1, and PD-L1 inhibitors are the extensively examined immune checkpoint blockers (ICB). CTLA-4/CD152, found on CD8+ and CD4+ T cells,157 critically activates or inhibits T cell-induced immune response. Among the current CTLA-4 inhibitors are Ipilimumab and Tremelimumab.82 PD-1/CD279 functions as a single-chain glycoprotein158 predominantly expressed on the membranes of various immune cells including T lymphocytes, B lymphocytes, NK cells, monocytic cells, DCs and tumor tissues.159 PD-1 is a major activated T cell immune checkpoint receptor, and it strongly modulates immune suppression. The current PD-1 inhibitors are Pembrolizumab, Pidilizumab, and Nivolumab. Among them, nivolumab is a fully humanized IgG4 mAb83 with remarkable clinical outcome. PD-L1 inhibits and inactivates T-cell via its association with the PD-1 and B7-1 receptors on stimulated T cells.160 Atezolizumab, a humanized anti-PD-L1 IgG-1 mAb,83 also enhances median OS and ORR among lung cancer patients.161 Relevant clinical trials are summarized in Supplemental Table 1. Androgen Receptor (AR) Approximately, 25–75% TNBC patients have enhanced AR expression level, among whom, the strongest expression is seen among patients with the LAR subtype.162 Using both in vitro and in vivo investigations, AR+ TNBCs were shown to respond well to AR antagonist therapy.163,164 Currently, three anti-AR drugs, Bicalutamide, Enzalutamide, and Seviteronel, are under clinical investigation.84 All available anti-androgen therapy-based clinical information are provided in Supplemental Table 1. Coding Genes Involved in Chemo-Sensitive and Chemo-Resistance of TNBC Unlike non-TNBC, TNBC are generally larger, of enhanced grade, and node positive. Hence, for TNBC, chemotherapy is the best treatment option.7 Among the recommended interventions are taxanes and anthracyclines, however, platinum-based regimens could be employed in neo-adjuvant settings.165 Taxanes are the primary constituents of neoadjuvant chemotherapy. Mechanically, they suppress microtubule depolymerization to repress cancer cell proliferation.166 TNBC patients are typically more responsive to neoadjuvant therapy than ER+ BC. They also have considerably worse OS, relative to non-TNBC tumor patients despite having better pCR rates; thus, this is known as the “triple negative paradox”.167 Given that chemotherapy is the main form of TNBC treatment, chemoresistance is the primary contributor of TNBC recurrence and metastasis. Currently, there is a lack of clinically employed bioindicators for sensitive or resistant tumor classification. Moreover, there are no treatment approaches geared toward the chemo-refractory cases.168 In this report, we first discussed the TNBC-associated chemotherapy-sensitivity and chemotherapy-resistance coding genes. The chemo-sensitive genes are strongly diminished in chemo-resistant TNBCs. It is speculated that future TNBC treatment may utilize overexpression of the chemo-sensitive genes (Figure 2 and Table 3). Alternatively, the chemo-resistant genes are ubiquitously expressed in chemo-resistant TNBC. Thus, future research may entail suppression of the aforementioned genes in TNBC (Figure 3 and Table 4). Due to the strongly altered states of these genes, they are served as strong candidates for estimating the chemotherapeutic response of TNBC patients, which, in turn, can assist in enhancing patient care and prognosis. However, whether these genes can become indicators of drug resistance in patients still has a long way to go. Table 3Chemotherapy-Sensitive Genes of TNBCGenesTarget GeneMedicationRefs.CLDN1Unknown pathwayPTX[169]DAB2IPRAC1-mediated β-catenin nuclear accumulationDocetaxel[170]TXNIPROS-based DNA damageDOX[171–173]C/EBP-β LIPPgpAnthracycline[174, 175]CREB3L1Unknown pathwayDoxorubicin[176]ATL-ICTGFPTX[177, 178]SLFN12CHK1 and CHK2PTX[179, 180]PAR-4Caspase-8Doxorubicin[181]ETS-1IKKα/NF-κB pathwayCisplatin[182] Table 4Chemotherapy-Resistant Genes of TNBCGenesTarget Gene/Signaling PathwayMedicineRef.SERCA2LC3BPTX[183]HORMAD1Apoptosis and AutophagyDocetaxel[184–187]TNFSF13AKT-mTORPTX[188]PPP1R14BSTMN1Paclitaxel[189]CENPFChk1Adriamycin[190–192]Notch1MVP/AKTCisplatin[193]HJURPHJURP/YAP1/NDRG1 axisDoxorubicin[194]BAIAP2L1RPL3/AKTDocetaxel[195]RASAL2MEK/EGFRCisplatin[168]SYTL4C2A domainPTX[196]MENAMAPK signalingPTX[197]Aurora-AFOXM1PTX[198]GRP78p-AKT/mTOR pathwayPirarubicin[199, 200]CXCL8Apoptosis signalingPTX[201, 202]BCKDKBCAA fluxDOX[203]PRKCQBimPTX; doxorubicin[204]PSMB5ApoptosisPTX[205]LIN9CCSAPPTX[206]PGK1XAF1PTX[207]SERPINE1VEGFAPTX[208]ATAD3APINK1PTX[209]TRA2ASplicing factorsPTX[210]HMGA1HMGA1/p27/stathminPaclitaxel[211, 212]IMP3ABCG2Doxorubicin[213]RAD6Microtubule dynamicsPTX[214]G6PDUnknown signalingDOX[215]NEK2Bβ-cateninPTX[216, 217]CERKUnknown signalingPaclitaxel; Cisplatin[218]RUNX1Unknown signalingPaclitaxel[219]DSTYKUnknown signalingDOX[220] Figure 2Genes promoting chemotherapeutic sensitivity in TNBC. Figure 3Genes promoting chemotherapeutic resistance in TNBC. Table 3Chemotherapy-Sensitive Genes of TNBCGenesTarget GeneMedicationRefs.CLDN1Unknown pathwayPTX[169]DAB2IPRAC1-mediated β-catenin nuclear accumulationDocetaxel[170]TXNIPROS-based DNA damageDOX[171–173]C/EBP-β LIPPgpAnthracycline[174, 175]CREB3L1Unknown pathwayDoxorubicin[176]ATL-ICTGFPTX[177, 178]SLFN12CHK1 and CHK2PTX[179, 180]PAR-4Caspase-8Doxorubicin[181]ETS-1IKKα/NF-κB pathwayCisplatin[182] Chemotherapy-Sensitive Genes of TNBC Table 4Chemotherapy-Resistant Genes of TNBCGenesTarget Gene/Signaling PathwayMedicineRef.SERCA2LC3BPTX[183]HORMAD1Apoptosis and AutophagyDocetaxel[184–187]TNFSF13AKT-mTORPTX[188]PPP1R14BSTMN1Paclitaxel[189]CENPFChk1Adriamycin[190–192]Notch1MVP/AKTCisplatin[193]HJURPHJURP/YAP1/NDRG1 axisDoxorubicin[194]BAIAP2L1RPL3/AKTDocetaxel[195]RASAL2MEK/EGFRCisplatin[168]SYTL4C2A domainPTX[196]MENAMAPK signalingPTX[197]Aurora-AFOXM1PTX[198]GRP78p-AKT/mTOR pathwayPirarubicin[199, 200]CXCL8Apoptosis signalingPTX[201, 202]BCKDKBCAA fluxDOX[203]PRKCQBimPTX; doxorubicin[204]PSMB5ApoptosisPTX[205]LIN9CCSAPPTX[206]PGK1XAF1PTX[207]SERPINE1VEGFAPTX[208]ATAD3APINK1PTX[209]TRA2ASplicing factorsPTX[210]HMGA1HMGA1/p27/stathminPaclitaxel[211, 212]IMP3ABCG2Doxorubicin[213]RAD6Microtubule dynamicsPTX[214]G6PDUnknown signalingDOX[215]NEK2Bβ-cateninPTX[216, 217]CERKUnknown signalingPaclitaxel; Cisplatin[218]RUNX1Unknown signalingPaclitaxel[219]DSTYKUnknown signalingDOX[220] Chemotherapy-Resistant Genes of TNBC Genes promoting chemotherapeutic sensitivity in TNBC. Genes promoting chemotherapeutic resistance in TNBC. Chemotherapy-Sensitivity Genes of TNBC CLDN1 Approximately 77% TNBC display little to no claudin-1 (CLDN1) expression, and this deficiency is strongly associated with worse outcome. One study reported that CLDN1 enhances TNBC cell line sensitivity to chemotherapeutic agents (paclitaxel, abbreviated as PTX) for BC therapy. These evidences confirm CLDN1 as a chemotherapeutic response indicator for TNBC patients.169 DAB2IP DAB2IP abrogates TNBC chemoresistance (Docetaxel) by suppressing the RAC1-triggered nuclear β-catenin transfer. Decitabine treatment re-expresses DAB2IP by preventing DNA methylation, thereby enhancing its potential in the management of TNBC.170 Thioredoxin-Interacting Protein (TXNIP) TXNIP originates from the α-arrestin family of proteins,171 which tightly modulate various physiological activities via interaction with other proteins.172 TXNIP accelerates cellular apoptosis, and inhibits chemo-resistant TNBC cellular growth both in vitro and in vivo by enhancing ROS-based DNA damage. The small molecular c-Myc inhibitor 10058-F4 enhances TXNIP content and augments intracellular ROS production to downregulate DOX-stimulated chemoresistance in TNBC. Combination with DOX further enhances the chemotherapeutic cytotoxic properties of 10058-F4.173 C/EBP-β LIP Doxorubicin effectiveness depends on the number of drug efflux transporters like P-glycoprotein (Pgp) present within tumor cells.174 One report revealed that blocking C/EBP-β LIP degradation strongly enhances nitric oxide content, while reducing Pgp expression and activity, which, in turn, restores ER stress-dependent apoptosis and Doxorubicin-induced immunogenic cell apoptosis. This, in turn, rescues the anthracycline therapeutic activity in Pgp-positive TNBC.175 cAMP Response Element Binding Protein 3-Like 1 (CREB3L1) Researchers reported high CREB3L1 levels in chemotherapeutic sensitive cancers than chemotherapeutic resistant cancers. Similarly, high CREB3L1-harboring TNBC responds better to doxorubicin-based chemotherapy than low CREB3L1-harboring TNBC.176 Atractylenolide-I (ATL-I) ATL-I exerts strong anti-tumor influences against BC.177 In particular, ATL-I reduces the CTGF transcript levels in TNBC, which reduces TNBC cell migration, diminishes the fibroblast to cancer-associated fibroblasts (CAFs) transformation, and enhances TNBC cell sensitivity to PTX.178 SLFN12 SLFN12 is a newly discovered protein, with strong association with TNBC patient prognosis.179 SLFN12 was shown to enhance TNBC cell sensitivity to radiation and cytotoxic drugs via reduction of CHK1 and CHK2 phosphorylation, which may be responsible for the OS differences between high and low SLFN12 tumor patients.180 Prostate Apoptosis Response-4 (PAR-4) PAR-4 deficiency in TNBC facilitates resistance to DNA damage-driven apoptosis, while simultaneously preventing caspase-8 activation. PAR-4 is downstream of caspase-8, and it functions by cleavage-triggered nuclear transfer of the C-terminal. Herein, researchers demonstrated that the nuclear transfer of the C-terminal PAR-4 fragment strongly depletes cIAP1, then activates caspase-8.181 ETS1 Strong evidence suggests that the ETS1 dysregulation is behind the cisplatin resistance of TNBC. This indicates that ETS1 overexpression can potentially enhance cisplatin chemosensitivity by augmenting ABC transporters via the IKKα/NF-κB axis.182 Chemotherapy-Resistance Genes of TNBC Autophagy-Related Genes SERCA2 SERCA2 is intricately linked to TNBC progression, and it enhances TNBC cell chemoresistance. SERCA2 was shown to interact with LC3B via the LIR motif in order to augment WIPI2-independent autophagosome production, which promotes autophagy.183 HORMA Domain‑containing Protein 1 (HORMAD1) HORMAD1 is a CTA with normal testicular expression, whereby it is engaged in essential physiological activities.184 In TNBC, however, it is expressed in substantially elevated levels.185,186 HORMAD1 modulates autophagy, and autophagic partially augments docetaxel-induced cellular apoptosis.187 TNFSF13 TNFSF13 accelerates autophagy and desensitizes TNBC cells to chemotherapy by inhibiting the AKT-mTOR axis. Hence, the TNFSF13-autophagy network is an excellent target for reversing TNBC chemoresistance.188 Cell Cycle-Related Genes Protein Phosphatase 1 Regulatory Subunit 14B (PPP1R14B) PPP1R14B belongs to the protein phosphatase 1 family of modulatory subunits, and it is strongly elevated in TNBC tissues. PPP1R14B augments STMN1-based α-tubulin acetylation, microtubular stability, and cell-cycle progression, which, in turn, facilitates TNBC cell resistance to PTX.189 CENPF CENPF expression is strongly elevated in TNBC, and it is linked to worse outcome in patients undergoing chemotherapy.190,191 In vitro CENPF deficiency strongly enhances adriamycin (ADR)‑driven cytotoxicity in MDA‑MB‑231 and ADR‑resistant cells (MDA‑MB‑231/ADR). CENPF also modulates the Chk1‑based G2/M phase arrest, and associates with Rb to sequester E2F1 in TNBC. Given the critical E2F1 role in DNA damage response and repair, discovery of a new signal transduction whereby CENPF modulates the Rb‑E2F1 network will enable a novel approach to overcoming chemoresistance in TNBC.192 Proliferation-Related Genes Notch1 Notch1 and major vault protein (MVP) are robust regulators of TNBC cell chemoresistance. It does so by modulating MVP expression to stimulate the AKT and EMT axes. Notch1 deficiency increases TNBC cell sensitivity to cisplatin-based chemotherapy.193 HJURP HJURP modulates Yes-Associated Protein (YAP1) protein ubiquitination to control its downstream transcriptional activity. In addition, YAP1 associated with the NDRG1 gene promoter to enhance gene transcription. Subsequently, the HJURP/YAP1/NDRG1 network modulates cell proliferation and doxorubicin resistance in TNBC. Together, these evidences indicate that the HJURP/YAP1/NDRG1 network modulation is essential in TNBC progression and therapeutic response.194 BAI-Associated Protein 2-Like 1 (BAIAP2L1) Excess BAIAP2L1 expression markedly induces BC proliferation potentially via AKT activation. Conversely, exposure to AKT inhibitor LY294002 diminishes BAIAP2L1 expression in BC cells. BAIAP2L1 interacts with the AA202-288 of ribosomal protein L3 (RPL3) within its SRC homology 3 (SH3) domain. In contrast, its deficiency abolishes AKT signaling to enhance PIK3CA degradation. Additionally, BAIAP2L1 overexpression enhances docetaxel resistance.195 RASAL2 Emerging evidences revealed that excess RASAL2 forms a chemotherapy-unresponsive TNBC subset. RASAL2 GAP function is critical for kinase inhibitor sensitivity, and RASAL2-high TNBCs maintain basal RAS activity via inhibition of negative feedback modulators SPRY1/2, along with EGFR elevation. As a result, RASAL2 expression reduces feedback compensation following MEK1/2 and EGFR co-suppression thereby inducing synergistic apoptosis in vitro and in vivo. Among TNBC patients, elevated RASAL2 contents indicate clinical chemotherapeutic response (Cisplatin).168 Synaptotagmin-Like 4 (SYTL4) SYTL4 is a relatively new chemo-resistant gene in TNBC. SYTL4 downregulation stabilizes the microtubular network by decelerating microtubular growth rate. Additionally, SYTL4 expresses alongside microtubules and interacts with the middle region of microtubules via a linker and C2A domain. SYTL4 also induces PTX resistance in TNBC in vitro and in vivo.196 MENA The MENA isoform disrupts the balance between dynamic and stable microtubules in PTX-exposed cells. Following PTX exposure, MENA activates MAPK. Conversely, following MEK inhibitor co-treatment, reduced ERK phosphorylation restores PTX sensitivity by enhancing microtubule stabilization in MENA isoform-harboring cells.197 Aurora Kinase A (Aurora‐A) Aurora‐A modulates FOXM1 in TNBC. Aurora‐A‐induced FOXM1 stabilization represents its kinase‐independent induction of augmented TNBC cell proliferative capacity. Even though Aurora‐A kinase inhibition is a potentially potent TNBC treatment regimen, the report indicated that the antibiotic drug thiostrepton usage, which downregulates Aurora‐A and FOXM1 contents, can work together with PTX to revert PTX chemoresistance in TNBC.198 GRP78 GRP78 is intricately linked to apoptosis, and GRP78 deficiency enhances BC apoptosis.199 GRP78 silencing strongly reduces MDR1 levels by negatively modulating the Akt/mTOR network in MDA-MB-231R cells.200 Furthermore, it reverts pirarubicin resistance of TNBC using miR-495-3p mimics and the p-AKT/mTOR axis.200 Apoptosis-Related Genes Cxcl8 CXCL8, otherwise called IL-8, originates from the proangiogenic chemokine family, and it is strongly linked to CXCR1/2.201 CXCL8 is ubiquitously present in PTX-resistant TNBC cells. In contrast, CXCL8 deficiency enhances TNBC cell sensitivity to PTX via regulation of the cell apoptosis network.202 Branched-Chain Ketoacid Dehydrogenase Kinase (BCKDK) Based on transcriptome analysis, BCKDK silencing dysregulates mitochondrial metabolic axes and upregulates the apoptotic axis. BCKDK suppression and simultaneous DOX exposure exacerbate apoptosis, caspase activity, and inhibition of TNBC proliferation. Collectively, BCKDK inactivity in TNBC alters BCAA flux, diminishes protein translation, thereby accelerating cell apoptosis, ATP insufficiency, and susceptibility toward genotoxic stress.203 PRKCQ Excess PRKCQ content strongly suppresses PTX- or doxorubicin-induced cell apoptosis. Conversely, PRKCQ deficiency enhances chemotherapy-induced TNBC cell apoptosis. PRKCQ modulates chemotherapy responsiveness by regulating Bim (a pro-apoptotic Bcl2 family member) content. Bim suppression abrogates the simultaneous PRKCQ deficiency- and chemotherapy treatment-induced cell apoptosis.204 Proteasome Subunit Beta 5 (PSMB5) Excess PSMB5 expression is strongly associated with worse TNBC patent outcome. In contrast, PSMB5 deficiency enhances TBNC cell apoptosis and augments chemotherapeutic sensitivity to PTX.205 LIN9 PTX-resistant TNBC cells have strongly elevated LIN9 content, relative to corresponding parental cells. LIN9 knockdown or PTX-resistant TNBC cell exposure to a bromo- and extra-terminal domain inhibitor (BETi) JQ1 substantially diminished LIN9 levels while enhancing PTX-resistant TNBC cell sensitivity to PTX. LIN9 suppression in resistant cell lines visibly reduces tumor cell survivability, increases multinucleated cell production, and enhances tumor cell apoptosis via direct regulation of CCSAP.206 PGK1 PGK1 silencing markedly increased TNBC cell line sensitivity to PTX therapy by enhancing drug-induced apoptosis. Moreover, PGK1-knockdown cells display excess XAF1, as well as apoptotic proteins cleaved caspase-3 and Bax expressions.207 SERPINE1 Enhanced SERPINE1 expression confers BC resistance to PTX treatment via elevation of VEGFA, and inhibition of cell apoptosis.208 Mitophagy-Related Genes ATAD3A PINK1 transports PD-L1 to the mitochondria for mitophagy-mediated destruction. PTX also increases ATAD3A content to impair PD-L1 proteostasis via modulation of PINK1-reliant mitophagy. In the clinics, tumor patients who have elevated ATAD3A levels prior to ICI and PTX co-treatment experienced substantially reduced PFS relative to those with ATAD3A-low tumors.209 Cancer-Related Splicing Genes Transformer2A (TRA2A) TRA2A promotes TNBC cell proliferation, survival, migration, and invasion. Additionally, TRA2A induces PTX resistance of TNBC cells via specific regulation of cancer-associated splicing, independent of other splicing factors.210 Microtubule-Destabilizing-Related Splicing Genes High Mobility Group A1 (HMGA1) HMGA1 is typically ubiquitously expressed during embryogenesis, and it declines to little or no expression in adults. However, it is strongly expressed in multiple tumors.211 The HMGA1/p27/stathmin network regulates TNBC cell motility. Therefore, HMGA1 silencing in TNBC cells strongly diminishes in stathmin content and action on microtubules. This, in turn, impairs cell motility in a p27-reliant fashion. Additionally, in a xenograft mouse model, HMGA1-depleted TNBC cells are more responsive to PTX treatment.212 ATP-Binding Cassette Transporter-Related Genes IMP3 BC resistance protein (BCRP), otherwise called ABCG2, belongs to the ATP-binding cassette transporter family. The IMP3 protein is reported to enhance chemoresistance (Doxorubicin) of BC cells via modulating ABCG2 levels.213 Unknown Signaling-Related Genes RAD6 SMI#9 (a RAD6 inhibitor) and PTX share the same mechanism of microtubular modulation. Therefore, the synergistic effect of both PTX and RAD6 inhibitor has potential advantages on enhancing TNBC sensitivities to PTX while eliminating toxicity. The aforementioned investigations were the first to uncover a role for RAD6 in modulating microtubule dynamics.214 Glucose-6-Phosphate Dehydrogenase (G6PD) Metastatic TNBC cells exhibit markedly elevated G6PD levels once DOX resistance form following lung metastasis. Moreover, G6PD suppression abrogates DOX resistance in the same mTNBC cells, while enhancing parental TNBC cell responsiveness to DOX.215 NEK2B Elevated Nek2B expression is intricately linked to worse disease-free survival (DFS) and OS in TNBC.216 Nek2B interacts with β-catenin to negatively regulate TNBC patient prognosis. Their synergistic action enhances TNBC chemo-resistance to PTX.217 Ceramide Kinase (CERK) Upregulated CERK activates numerous oncogenic networks to promote chemo-resistance in TNBC cells. Additionally, excess CERK expression heavily influences chemo-sensitivity (PTX and cisplatin), and therefore serve as a potential bioindicator of chemo-resistance risk classification in newly diagnosed TNBC patients.218 RUNX1 Suppression of RUNX1 transcriptional activity strongly enhances chemotherapy sensitivity in (AR+) TNBC cell lines both in culture and forced suspension. Pharmacologic RUNX1 suppression also augments the effects of the aforementioned combinational treatments (PTX).219 DSTYK One investigation knocked out DSTYK using the CRISPR/Cas9 method, and revealed considerable chemo-resistant cell death following drug intervention. In addition, DSTYK knockout enhances the chemotherapeutic drug-driven tumor cell apoptosis in an orthotopic mouse model. Collectively, these results indicate that DSTYK is essential for DOX chemoresistance.220 Potential Novel Therapeutic Targets for TNBC Considering the aforementioned TNBC-based evidences, a detailed and extensive list of chemotherapy, as well as existing and ongoing targeted molecular therapy including the following: (1) chemotherapy; (2) DRR axis inhibitors (targeting BRCA, ATR-CHK1-WEE1); (3) proliferation-associated network inhibitors (targeting PI3K-AKT-mTOR; NOTCH; RB; EGFR); (4) ICBs (targeting PD-L1/PD-1); (5) AR inhibitor. With emerging investigations, more researchers have proposed additional approaches to treating TNBC. Here, we have summarized the most current potential TNBC therapies, namely, ferroptosis-associated network; potential targeted ADC markers; Ceritinib; Src Inhibitor; CDK12/CDK13 inhibitor. All TNBC-related therapies and medications are presented in Figure 4 and Table 2. Figure 4An illustration of all available therapeutic means of TNBC including the DNA damage pathway, immunotherapy, chemotherapy, proliferation pathway, androgen receptor, potential therapeutic pathway. An illustration of all available therapeutic means of TNBC including the DNA damage pathway, immunotherapy, chemotherapy, proliferation pathway, androgen receptor, potential therapeutic pathway. Ferroptosis-Associated Network Twelve genes linked to ferroptosis were analyzed for prognostic evaluation in TNBC cases, with seven genetic markers (ASNS, LAMP2, CAV1, DPP4, HELLS, TF, ZFP69B) emerging as viable therapeutic candidates. Additionally, two pharmaceutical compounds (1-methyl-3-isobutylxanthine and rosiglitazone) demonstrated potential efficacy in TNBC treatment scenarios.85 Potential Targeted ADC Bioindicators ADC enhances high cytotoxic drug concentration delivery to ADC-containing cells.86 Sacituzumab govitecan (IMMU-132) is an SN-38 conjugate Trop-2-targeting antibody. Trop-2 is present in approximately 90% of all TNBCs.87 Ladiratuzumab Vedotin (SGN-LIV1A), with monomethyl-auristatin-E (MMAE) as the payload, achieves a 25% ORR and median PFS of 11 months among TNBC patients. Excess glycoprotein-NMB (gpNMB) expression, indicated by ≥25% of tumor epithelial cell staining, occurs in about 40% of TNBCs, and in this subgroup, glembatumumab vedotin (CDX-011, an ADC that interacts with gpNMB to deploy MMAE) achieves 40% ORR versus 0% with the author´s therapy of choice.88 Some new ADC medicines have also been created and engaged in clinical trials. AVID100 is an anti-EGFR ADC that targets EGFR and is conjugated with DM1.89 U3-1402 is an anti-HER3 ADC that is conjugated with a topoisomerase I inhibitor exatecan derivative via a peptidyllinker.221 CAB-ROR2-ADC is an ADC composed of a conditionally active biologic antibody directing receptor tyrosine kinase-like orphan receptor 2 (ROR2) conjugated to an undisclosed payload.89 Anti-CA6-DM4 immunoconjugate (SAR566658) is a humanized DS6 antibody directed against CA6 conjugated to DM4.89 New targeted for ADC drug development is the most potential direction for TNBC therapy. Ceritinib Ceritinib, an FDA-approved anti-lung cancer medication,90 significantly inhibits LAR TNBC development. Additionally, Activated CDC42 Kinase 1 (ACK1) is a strong ceritinib target in LAR TNBC cells, whereby ceritinib inactivates the RTK-ACK1/FAK-AR network in LAR TNBC cells. Lastly, this investigation established a new treatment approach for AR+ TNBC tumors involving a combinational therapy for AR− or AR low TNBCs.91 Src Inhibitor Src is a specific tyrosine kinase that has gained recognition as a possible target for multi-cancer treatment.92,93 Prior investigations by Finn et al94 reported that TNBC cell lines are especially responsive to dasatinib, whereas, Huang et al demonstrated that a BC subgroup harboring the dasatinib-responsive signature includes patients with TNBC.95 It was also revealed that dasatinib suppresses different TNBC cellular growth in culture. However, Src content or phosphorylation failed to indicate dasatinib responsiveness in vitro.96 CDK12/CDK13 Inhibitor CDKs are serine/threonine kinase activities are heavily reliant on their association with the cyclin modulatory subunit.222 The CDK enzyme family modulates the cell cycle and transcription processes.223 Quereda et al established a targeted dual CDK12/CDK13 inhibitor (SR-4835) that diminishes core DNA damage response gene expressions by upregulating intronic polyadenylation site cleavage, which results in impaired DNA damage repair, thereby increasing cellular responsiveness to DNA-damaging agents and PARP inhibitors.97 Conclusion and Future Perspective TNBC is a disease marked by enhanced heterogeneity and poor prognosis. Unlike HR-positive BC, TNBC is correlated with a younger patient age, increased visceral metastases risk, enhanced early recurrence risk, and extremely poor outcome.9,224,225 Therapy for TNBC patients, who lack ER and PR expressions as well as HER2 amplification, is quite challenging due to the heterogenic characteristic of this disease, as well as the lack of well-established molecular targets.167,226,227 Gene expression profiling-related molecular TNBC subtyping is critical for elucidating the underlying mechanisms of this disease, which, in turn, will benefit personalized treatment.29 Hence, an extensive exploration of all subtypes and properties is crucial. Additionally, newly discovered subtype stratification enables clinicians to better manage TNBC. As a result, given the poor outcome of TNBC patients, it is essential to gain an extensive comprehension of the disease, particularly, in relation to the following aspects: (a) DDR-associated BRCA Loss-Function Mutation; (b) PI3K axis; (c) NOTCH network; (d) CDK-Rb axis; (e) EGFR Activation; (f) Angiogenesis network; (g) HER2-Low; (h) DDR signal transduction; (i) Immunotherapy and (j) AR signaling. Based on the aforementioned genes and aberrant signal networks, scientists have developed potential targeted therapies, as is presented in Table 2. The relevant clinical trials are summarized in Supplemental Table 1. It is our hope and speculation that the mentioned medications will be incredibly advantageous to TNBC therapy in near future. Notably, with the emergence of the HER2-low concept, drugs targeting HER2-low are being proposed and placed in clinical trials. Furthermore, given that chemotherapy is the standard intervention for TNBC, herein, we summarized the coding genes associated with TNBC chemoresistance, which may eventually be targets of future TNBC therapy. Additionally, we also listed the known chemo-sensitive and chemo-resistance genes associated with TNBC. Moreover, the CLDN1, DAB2IP, TXNIP, C/EBP-β LIP, CREB3L1, ATL-1, SLFN12, PAR-4, and ETS-1 genes may can be used to predict patient sensitivity to chemotherapy or neoadjuvant-chemotherapy in the clinic. Similarly, the HJURP, CXCL8, SERCA2, PPP1R14B, HORMAD1, DSTYK, Notch1, and CENPF genes serve as indicators of patient resistance to chemotherapy in the clinic. We speculate that the aforementioned chemo-sensitive and chemo-resistant genes will be examined further in coming years for the development of better anti-TNBC therapy. We also discussed the emergence of new treatments for TNBC, namely, the ferroptosis-associated network, ADC, Ceritinib, Src inhibitor, and CDK12/CDK13 inhibitor. Considering that the aforementioned drugs continue to show benefit against TNBC, they may enter clinical trials relatively soon, and be administered to TNBC patients in the clinic. In summary, this review presents an extensive overview of the gene mutation profile of TNBC, as well as the corresponding targeted immune- and chemotherapies. This will provide a direction and beacon for the development of highly efficacious future TNBC therapy.